By addressing translational challenges and tackling off-target toxicities, the 2nd ADC Toxicity Summit is returning at an imperative time to allow you to prevent, predict and mitigate toxicities ...

Duality Biologics has begun (PDF) offering stock, wading into a market reeling from Presid | Duality Biologics has begun ...

Antibody-drug conjugates are a significant evolution in drug development landscape: Dr. Kenneth Barr: Nandita Vijayasimha, Bengaluru Saturday, April 12, 2025, 08:00 Hrs [IST] Anti ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created ...

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for ...

A resurgence of interest One reason that ADCs struggled to gain traction is due to their potential for toxicity. Mylotarg (gemtuzumab ozogamicin) is an ADC created by Pfizer and approved in 2000 ...

Day One Biopharmaceuticals' Ojemda sees $57.2M in 2024 sales amid biotech pullback. DAWN's stock is near 52-week lows. Read ...

The Illinois House passed a bill Thursday night to ban companies from manufacturing, selling, and distributing firefighting ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

BriaCell Therapeutics Corp. ("BriaCell"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary, BriaPro Therapeutics ...

To the delight of Wyoming’s top elected officials, President Donald Trump signed a series of executive orders Tuesday to ...